Mutations found in myeloma patients
A novel WINDOW of opportunity for young mantle cell lymphoma patients
Can we target AML with CAR T-cells?
Recent developments in the mutational landscape and molecular basis of AML
The importance of diagnosing DLBCL on a molecular level and how it will improve treatment